Zypan Functional Dyspepsia

Inclusion Criteria:

• ● Adults 18-70 years of age (inclusive)

• A self-reported history of symptoms consistent with Functional Dyspepsia (perRome IV criteria - See Telephone Screening), and self-reported absence oforganic disease and infection (e.g., Helicobacter pylori) with or without aformal diagnosis by a healthcare professional.

• Adults ≥ 60 years of age must have had a normal upper gastrointestinalendoscopy

• Willing to be randomized to take a daily dietary supplement or placebo over the 4-week study period

• Not taken antibiotics or other drugs prescribed specifically for symptomsconsistent with Functional Dyspepsia (per Rome IV criteria) for a period up to 1 month before the beginning of the study.

• On a stable dose of all medications prior to study entry (i.e., consistent dosefor a minimum of three months)

• On a stable dose of dietary supplements for at least one month prior toenrollment

• Willing to avoid initiation of new supplements and/or medications unlessotherwise indicated by a healthcare professional

• Able to communicate via email, complete computer-administered questionnaires,and to read and write in English.

• Approved to be eligible for study participation at the discretion of thePrincipal Investigators, after review of the Formal Eligibility Screen results.

• Non-smokers (including tobacco and cannabis products, combusted or vaporized)

• Willing to provide written informed consent and to follow the required protocol

Exclusion Criteria:

• ● A self-reported history of peptic and/or duodenal ulcers, H. pylori infection,gastroesophageal reflux disease (GERD) explained by upper endoscopy, irritable bowelsyndrome (IBS), and other chronic GI disorders.

• Positive fecal occult blood test (FOBT) at the clinical screening visit

• Current use of digestive enzyme and/or betaine HCL-containing dietarysupplements

• Current use of prescribed proton-pump inhibitors

• Current use of drugs that interfere with gastrointestinal motility, includingprokinetic agents.

• History of previous abdominal surgery, including gastric surgery, excludingappendectomy.

• Individuals with chronic kidney or liver disease, cancer, colorectal diseaseand/or other rare disorders that at the discretion of the PI or ClinicalInvestigator may impact their safety or confound trial results

• Current involvement or within 14 days prior to screening of a significant dietor weight loss program (such as NutriSystem, Jenny Craig, Atkin's or otherlow-carb diet programs) or very low-calorie liquid diet programs (such asOptifast, Medifast, and/or HMR)

• Hospitalization (for any reason other than a scheduled medical procedureunrelated to Functional Dyspepsia) within 3 months prior to screening

• Malignancy within the last 5 years (with the exception of basal cell carcinoma,squamous cell carcinoma, and/or carcinoma in situ of the cervix)

• Intake of ≥ 2 standardized alcohol-containing beverages per day, 14 per week,or ≥4 in any single day within the past 14 days.

• Individuals who do not consume, or are allergic to, animal products

• Smoking tobacco or nicotine products (combusted or vaporized)

• Use of illicit drugs/substances (such as but not limited to cocaine,phencyclidine (PCP), and methamphetamine) within 14 days of screening

• Currently participating in another interventional research study, orparticipated in another interventional research study within 14 days ofscreening